Fig. 2

Overview of the possibly affected organs in LCFAOD (A) and the current approach to long-term monitoring of LCFAOD in Europe (B). Follow-up procedures are categorized in three groups: 1 used for clinical decision making (upper box), 2 mostly used to gain insight in disease course (middle box) and 3 without clear clinical implications (lower box). Future insight in disease course of the new NBS-population may allow re-categorization of follow-up procedures into relevant for clinical decision making or without clear clinical implications. LCFAOD Long chain fatty acid oxidation defects, LCHADD Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, MTPD Mitochondrial trifunctional protein deficiency, NBS Newborn screening, QoL Quality of life, CK Creatine kinase